157 related articles for article (PubMed ID: 22940072)
1. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease.
Zerr P; Distler A; Palumbo-Zerr K; Tomcik M; Vollath S; Dees C; Egberts F; Tinazzi I; Del Galdo F; Distler O; Schett G; Spriewald BM; Distler JH
Am J Pathol; 2012 Nov; 181(5):1672-80. PubMed ID: 22940072
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease.
Zerr P; Palumbo-Zerr K; Distler A; Tomcik M; Vollath S; Munoz LE; Beyer C; Dees C; Egberts F; Tinazzi I; Del Galdo F; Distler O; Schett G; Spriewald BM; Distler JH
Blood; 2012 Oct; 120(14):2909-17. PubMed ID: 22915638
[TBL] [Abstract][Full Text] [Related]
3. Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease.
Belle L; Fransolet G; Somja J; Binsfeld M; Delvenne P; Drion P; Hannon M; Beguin Y; Ehx G; Baron F
PLoS One; 2016; 11(12):e0167997. PubMed ID: 27942010
[TBL] [Abstract][Full Text] [Related]
4. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
[TBL] [Abstract][Full Text] [Related]
5. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Beyer C; Distler JH; Distler O
Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.
Magro L; Catteau B; Coiteux V; Bruno B; Jouet JP; Yakoub-Agha I
Bone Marrow Transplant; 2008 Dec; 42(11):757-60. PubMed ID: 18762765
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
Distler JH; Distler O
Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
[TBL] [Abstract][Full Text] [Related]
8. Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.
Molés-Poveda P; Montesinos P; Sanz-Caballer J; de Unamuno B; Piñana JL; Sahuquillo A; Botella-Estrada R
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):241-247. PubMed ID: 29254596
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.
Hinchcliff M; Huang CC; Ishida W; Fang F; Lee J; Jafari N; Wilkes M; Bhattacharyya S; Leof E; Varga J
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S86-96. PubMed ID: 22691216
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of radiation-induced skin fibrosis with imatinib.
Horton JA; Chung EJ; Hudak KE; Sowers A; Thetford A; White AO; Mitchell JB; Citrin DE
Int J Radiat Biol; 2013 Mar; 89(3):162-70. PubMed ID: 23083077
[TBL] [Abstract][Full Text] [Related]
12. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
Distler JH; Distler O
Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v10-1. PubMed ID: 18784126
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis.
Akhmetshina A; Dees C; Pileckyte M; Maurer B; Axmann R; Jüngel A; Zwerina J; Gay S; Schett G; Distler O; Distler JH
FASEB J; 2008 Jul; 22(7):2214-22. PubMed ID: 18326784
[TBL] [Abstract][Full Text] [Related]
14. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.
de Masson A; Bouaziz JD; Peffault de Latour R; Wittnebel S; Ribaud P; Rubio MT; Micol JB; Suarez F; Nguyen S; Dalle JH; Yakouben K; Robin M; Xhaard A; Adès L; Bourhis JH; Rybojad M; Bagot M; Socié G
Blood; 2012 Dec; 120(25):5089-90. PubMed ID: 23243159
[No Abstract] [Full Text] [Related]
15. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
16. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors.
Maurer B; Distler A; Dees C; Khan K; Denton CP; Abraham D; Gay RE; Michel BA; Gay S; Hw Distler J; Distler O
Ann Rheum Dis; 2013 Dec; 72(12):2039-46. PubMed ID: 24013728
[TBL] [Abstract][Full Text] [Related]
17. Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease.
Zhang Y; Shen L; Dreißigacker K; Zhu H; Trinh-Minh T; Meng X; Tran-Manh C; Dees C; Matei AE; Chen CW; Ditschkowski M; Krauss S; Winkler J; Wolff D; Ziemer M; Beilhack A; Karrer S; Herr W; Mackensen A; Schett G; Spriewald BM; Distler JHW
Blood; 2021 Apr; 137(17):2403-2416. PubMed ID: 33529322
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.
Daniels CE; Wilkes MC; Edens M; Kottom TJ; Murphy SJ; Limper AH; Leof EB
J Clin Invest; 2004 Nov; 114(9):1308-16. PubMed ID: 15520863
[TBL] [Abstract][Full Text] [Related]
19. Anti-CX3CL1 (fractalkine) monoclonal antibody attenuates lung and skin fibrosis in sclerodermatous graft-versus-host disease mouse model.
Hasegawa T; Utsunomiya A; Chino T; Kasamatsu H; Shimizu T; Matsushita T; Obara T; Ishii N; Ogasawara H; Ikeda W; Imai T; Oyama N; Hasegawa M
Arthritis Res Ther; 2024 May; 26(1):94. PubMed ID: 38702742
[TBL] [Abstract][Full Text] [Related]
20. Blockade of p38 Mitogen-Activated Protein Kinase Inhibits Murine Sclerodermatous Chronic Graft-versus-Host Disease.
Matsushita T; Date M; Kano M; Mizumaki K; Tennichi M; Kobayashi T; Hamaguchi Y; Hasegawa M; Fujimoto M; Takehara K
Am J Pathol; 2017 Apr; 187(4):841-850. PubMed ID: 28189565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
